Association of CCL5 rs2107538, and CCL2 rs3760396 Gene Polymorphisms with the Risk of Cardiovascular Disease.
CC chemokines ligand 5, 2
Cardiovascular disease
Genetic polymorphism
Journal
Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
11
05
2020
accepted:
10
07
2020
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
ppublish
Résumé
Chemokines are proinflammatory cytokines that play key roles in development of cardiovascular diseases (CVD). Chemokine-induced recruitment of peripheral leucocytes to tissues is a crucial step in the CVD progression. CC chemokines ligand 5, 2 (CCL5 and CCL2), have been characterized as emerging inflammatory biomarkers of atherosclerotic CVD. The aim of this study was to find out whether genetic polymorphisms of CCL5 -403 G>A (rs2107538) and CCL2 -927 G>C, (rs3760396) were associated with the risk of CVD. In this case-control study, 500 Iranian individuals including 250 CVD patients and 250 healthy subjects as the control group participated in 2017. Genotyping of CCL5 -403 G>A and CCL2 -927 G>C polymorphisms were executed using Tetra-ARMS PCR method. At genotypic level both CCL5 -403 G>A and CCL2 -927 G>C polymorphisms were not associated with the risk of CVD ( CCL2 -927 C variant and CCL5/CCL2 haplotype (G/C) were associated with susceptibility to CVD, and were risk factors for CVD in our population but more studies with large sample size are recommended.
Sections du résumé
BACKGROUND
BACKGROUND
Chemokines are proinflammatory cytokines that play key roles in development of cardiovascular diseases (CVD). Chemokine-induced recruitment of peripheral leucocytes to tissues is a crucial step in the CVD progression. CC chemokines ligand 5, 2 (CCL5 and CCL2), have been characterized as emerging inflammatory biomarkers of atherosclerotic CVD. The aim of this study was to find out whether genetic polymorphisms of CCL5 -403 G>A (rs2107538) and CCL2 -927 G>C, (rs3760396) were associated with the risk of CVD.
METHODS
METHODS
In this case-control study, 500 Iranian individuals including 250 CVD patients and 250 healthy subjects as the control group participated in 2017. Genotyping of CCL5 -403 G>A and CCL2 -927 G>C polymorphisms were executed using Tetra-ARMS PCR method.
RESULTS
RESULTS
At genotypic level both CCL5 -403 G>A and CCL2 -927 G>C polymorphisms were not associated with the risk of CVD (
CONCLUSION
CONCLUSIONS
CCL2 -927 C variant and CCL5/CCL2 haplotype (G/C) were associated with susceptibility to CVD, and were risk factors for CVD in our population but more studies with large sample size are recommended.
Identifiants
pubmed: 34568183
doi: 10.18502/ijph.v50i7.6634
pii: IJPH-50-1436
pmc: PMC8426758
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1436-1444Informations de copyright
Copyright © 2021 Mohtavinejad et al. Published by Tehran University of Medical Sciences.
Références
Thromb Res. 2009 May;124(1):84-9
pubmed: 19201454
Br J Pharmacol. 2011 Apr;162(7):1453-69
pubmed: 21133894
Eur Heart J. 2004 Aug;25(16):1438-46
pubmed: 15302103
Clin Sci (Lond). 2007 Oct;113(8):349-56
pubmed: 17504241
Immunol Lett. 2016 Aug;176:128-38
pubmed: 27262929
Circulation. 1998 Mar 31;97(12):1136-43
pubmed: 9537339
Mediators Inflamm. 2011;2011:525691
pubmed: 21547257
Saudi Med J. 2015 Dec;36(12):1400-7
pubmed: 26620981
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):194-9
pubmed: 16239601
Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):718-26
pubmed: 23288157
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Nov;150(2):191-204
pubmed: 17426779
Clin Sci (Lond). 2009 Jul 02;117(3):95-109
pubmed: 19566488
Eur Heart J. 2011 Jun;32(11):1345-61
pubmed: 21531743
PLoS One. 2012;7(10):e47211
pubmed: 23071760
BMC Genomics. 2009 Jan 09;10:13
pubmed: 19134193
PLoS One. 2011;6(12):e25734
pubmed: 22162987
Atherosclerosis. 2006 May;186(1):146-51
pubmed: 16099464
Atherosclerosis. 2005 Nov;183(1):121-9
pubmed: 15899487
Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1460-6
pubmed: 20431065
Stroke. 2006 Jul;37(7):1691-6
pubmed: 16741188
Genes Immun. 2006 Oct;7(7):544-9
pubmed: 16855620
Int J Immunogenet. 2013 Aug;40(4):306-10
pubmed: 23198952
Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):726-31
pubmed: 16614115
J Interferon Cytokine Res. 2002 Feb;22(2):223-9
pubmed: 11911805
Cytokine. 2007 Jan;37(1):44-50
pubmed: 17382553
Am J Hum Genet. 2007 Mar;80(3):577-9
pubmed: 17380613
Diab Vasc Dis Res. 2007 Jun;4(2):136-42
pubmed: 17654448
Cerebrovasc Dis. 2010 Feb;29(3):242-7
pubmed: 20029197
Gene. 2013 Nov 15;531(1):71-7
pubmed: 23906684
Circulation. 2005 Aug 23;112(8):1113-20
pubmed: 16116069